Stay updated on T-DM1 & Tucatinib in HER2+ Breast Cancer Clinical Trial
Sign up to get notified when there's something new on the T-DM1 & Tucatinib in HER2+ Breast Cancer Clinical Trial page.

Latest updates to the T-DM1 & Tucatinib in HER2+ Breast Cancer Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedRecord History now shows Revision: v3.6.4 replacing v3.6.3, indicating a small update to the page's versioning.SummaryDifference0.1%

- Check21 days agoNo Change Detected
- Check28 days agoNo Change Detected
- Check35 days agoChange DetectedA new revision entry v3.6.3 was added to the study's revision history, and the older revision v3.6.0 was removed from the list, reflecting an update to the record's version history.SummaryDifference0.1%

- Check49 days agoChange DetectedThe latest version adds core study metadata sections such as Contacts/Locations, Eligibility, Outcome Measures, Arms and Interventions, Conditions, Study Description, Study Status, and Study Identification. It also notes that recruitment is no longer looking for participants, signaling that the trial is not actively enrolling.SummaryDifference2%

- Check57 days agoChange DetectedA new revision entry (Revision: v3.5.5) is added to the study history, and the previous entry (Revision: v3.5.4) is removed from the list, updating the record to reflect the latest version.SummaryDifference0.1%

- Check78 days agoChange DetectedA new version entry, Revision: v3.5.4, was added to the Record History, replacing the previous Revision: v3.5.3 and signaling an update to the study record.SummaryDifference0.1%

- Check100 days agoChange DetectedThe page now displays an updated UI/release revision label (Revision: v3.5.3 instead of v3.5.2), reflecting a site/version update rather than a change to the underlying study record.SummaryDifference0.1%

Stay in the know with updates to T-DM1 & Tucatinib in HER2+ Breast Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the T-DM1 & Tucatinib in HER2+ Breast Cancer Clinical Trial page.